WuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for Gaucher Disease by China NMPA

WuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for…

Regeneron Provides Update on EYLEA HD ® (aflibercept) Injection 8 mg Supplemental Biologics License Application

Regeneron Provides Update on EYLEA HD ® (aflibercept) Injection 8 mg Supplemental Biologics License Application#Regeneron #Update…

Three-Year Results for EYLEA HD ® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended

Three-Year Results for EYLEA HD ® (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular…